SOURCE: Provalis PLC

July 26, 2005 02:01 ET

Provalis announces Update on in2it

Deeside, Flintshire, UK -- (MARKET WIRE) -- July 26, 2005 --Provalis plc

Update on progress of in2it™ A1c

Provalis plc (LSE: PRO; NASDAQ: PVLS), the international medical diagnostics and pharmaceuticals group, is today providing an update on the progress of its flagship product for the diabetes market, in2it™ A1c.

Shipments of the enhanced in2it™ A1c cartridge have now commenced to the USA, as envisaged in Provalis' June statement. The upgraded analyzer was already in production and all existing distributors are being restocked with both the upgraded analyzer and cartridges. In addition, the next phase of the planned expansion of the cartridge manufacturing capacity is now available, on schedule, to meet expected demand through the rest of this year and into 2006. Supplies will build steadily over the next few months and will utilise this increased cartridge manufacturing capacity.

Phil Gould, Chief Executive Officer of Provalis said,

"We have rapidly made the small design changes to the cartridge manufacturing process and have already started to ship the enhanced product to the USA. Demand remains strong for a cost-effective and easy-to-use glycated haemoglobin testing product for diabetes, given over 17 million Americans are directly affected."

                                                            26 July 2005

For further information:-

Provalis plc
Dr Phil Gould, Chief Executive Officer                        01244 833463
Peter Bream, Finance Director                                 01244 833552

College Hill
Adrian Duffield/Corinna Dorward,                        020 7457 2815/2803

Notes to Editors

Provalis plc (LSE: PRO; NASDAQ: PVLS) is an international healthcare group with two operating businesses:-

* Medical Diagnostics - develops medical diagnostic products for chronic 
  disease management for sale to world markets. The business' principal 
  products are in2it(TM) A1c and Glycosal(R), both diabetes diagnostic 
* Pharmaceuticals - sells and markets its own, and third party, branded, 
  prescription medicines in the UK and Ireland to GPs and hospitals 
  through its regionally managed sales force. The business' principal 
  product is Diclomax(R), a medicine for use in the treatment of 
  musculo-skeletal disorders, and it also sells products in the areas of 
  osteoporosis, migraine and dermatology. 


Visit Provalis' Revised Website at

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Statements in this announcement that relate to future plans, expectations, events, performances and the like are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors. Such factors include, among others: the viability of the Group's products, which are at various stages of development; the generation of sufficient operating cash flow by the Group's pharmaceutical and medical diagnostic businesses to finance the ongoing development of these businesses as well as the Group's research and development activities; the success of the Group's research and development strategy and activities; uncertainties related to future clinical trial results and the associated regulatory process; the execution and success of collaborative agreements with third parties; availability and level of reimbursement for the Group's products from government health administration authorities or other third-party payors; the rate of net cash utilisation within the Group and, hence, the Group's possible need for additional capital in the short, medium and/or long term; the Group's intellectual property position and the success of patent applications for its products and technologies; the Group's dependence on key personnel; general business and economic conditions; the impact of future laws, regulations and policies; stock market trends in the Group's sector; and other factors beyond the Group's control that may cause the Group's available capital resources to be used more quickly than expected. These and other factors that could affect the Company's future results are more fully described in its filings with the US Securities and Exchange Commission, in particular the latest 20-F filing, copies of which are available from the Company Secretary at the Company's registered address.

                      This information is provided by RNS
            The company news service from the London Stock Exchange